Schoepfer Alain M, Straumann Alex, Safroneeva Ekaterina
Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois (CHUV), Rue de Bugnon 44, 07/2409, Lausanne 1011, Switzerland.
Swiss EoE Clinic, Römerstrasse 7, 4600 Olten, Switzerland; Division of Gastroenterology and Hepatology, Department of Internal Medicine, University Hospital Zurich, Rämistrasse 100, 8091 Zürich, Switzerland.
Gastrointest Endosc Clin N Am. 2018 Jan;28(1):77-88. doi: 10.1016/j.giec.2017.07.007. Epub 2017 Oct 7.
Eosinophilic esophagitis (EoE) is defined as a chronic, immune-medicated or antigen-mediated, esophageal disease, characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation. Food allergens are identified in most patients. Treatment strategies include elimination diets, drugs, and esophageal dilation. This article focuses on pharmacologic treatment. Currently, there is no pharmacologic treatment that has been approved by regulatory authorities. Established pharmacologic options to treat EoE include proton pump inhibitors and swallowed topical steroids. Several biologic therapies are currently under evaluation and some of them have shown promising results in improving biologic endpoints and patient-reported outcomes.
嗜酸性食管炎（EoE）被定义为一种慢性、免疫介导或抗原介导的食管疾病，临床特征为与食管功能障碍相关的症状，组织学特征为以嗜酸性粒细胞为主的炎症。大多数患者可识别出食物过敏原。治疗策略包括饮食剔除、药物治疗和食管扩张。本文重点关注药物治疗。目前，尚无经监管机构批准的药物治疗方法。已确立的治疗EoE的药物选择包括质子泵抑制剂和吞咽局部用类固醇。目前有几种生物疗法正在评估中，其中一些在改善生物学终点和患者报告的结局方面已显示出有前景的结果。
